Korean Market
EXCH
Genome &
★

Genome & Company Announces Conversion of 1.28M Preferred Shares to Common Shares, Leading to 2.5% Dilution

 
EXCH
Genome &
★

Genome & Company Reports Conversion of 2.52 Million Preferred Shares into Common Shares, Diluting Existing Shareholders by 5.2%

 
EXCH
Genome &
★

Genome & Company's Conversion of 3.1M Preferred Shares to Common Dilutes Existing Shareholders by 6.85%

 
EXCH
Genome &
★

Genome & Company Sets Record Date for Extraordinary General Meeting

 
EXCH
Genome &
★

Genome & Company Board Resolves to Convene Temporary Shareholders Meeting with Details to Follow

 
OWNR
Genome &
★

Non-registered executive Cha Mi-young receives 20,000 shares as gift from CEO... ownership ratio unchanged at 0.10%

 
OWNR
Genome &
★★

Genome & Company's largest shareholder Park Han-su's stake plunges from 15.67% to 9.65% due to gifts and dilution from new share issuance, raising dilution risk

 
OWNR
Genome &
★

CEO Park Han-su donates 20,000 shares to employees, stake drops from 10.07% to 6.04%

 
OWNR
Genome &
★

Paratus New Normal TCB Private Investment drastically reduces stake from 6.81% to 2.91% via CB conversion and on-market sale... simple investment purpose sale raises downside pressure on stock price

 
OWNR
Genome &
★

DSC Investment reduces stake in Genome & Company from 6.53% to 4.30% via CB conversion and open market sales, raising dilution concerns

 
EXCH
Genome &
★

8,548,956 Shares Conversion Exercise - 18.62% of Total Issued Shares

 
PERI
Genome &
★

Genome&Company: Q1 2026 Operating Loss Widens but Fundraising Succeeds, Pipeline Progresses

 
OTHR
Genome &
★

Genome & Co. Files Amendment to Stock Option Grant (Reduced Grantees and Shares)

 
OTHR
Genome &
★

Genome & Company Corrects Stock Option Grant – Exercise Price Sharply Reduced, Shares Increased

 
OTHR
Genome &
★

Genom&Company corrects stock option grant: lower exercise price and increased shares